A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients

Summary

Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)

Timeline

Start

2014-11-05

Primary completion

2017-01-17

Completion

2017-01-17

Outcome

Met primary endpoint

registry analysis (superiority or other test); Ranibizumab (RFB002) vs Laser; p <0.001; Least Squares Mean Difference 5.8 (95% CI 4.1 to 7.5); Cochran-Mantel-Haenszel NCT02259088 ↗

Drugs

Indications